(Q38053670)

27 August 2017

title

Immunotherapy for castration-resistant prostate cancer (English)

1 reference

27 August 2017

1 reference

2

Philip W Kantoff

1 reference

27 August 2017

Guru Sonpavde

1

1 reference

27 August 2017

publication date

1 November 2012

1 reference

Urologic Clinics of North America

27 August 2017

published in

1 reference

27 August 2017

volume

39

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

465-481

1 reference

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Tumor escape mechanisms in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

The role of prostaglandin synthesis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Analysis of type T1 and T2 cytokines in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Enhancing the efficacy of cancer vaccines in urologic oncology: new directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Cancer-related inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

The role of myeloid cells in the promotion of tumour angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Molecular characterization of defective antigen processing in human prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Prostaglandins and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Pox viral vaccine approaches.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Prostate cancer as a model for tumour immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Update on anti-CTLA-4 antibodies in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Radiotherapy augments the immune response to prostate cancer in a time-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

The B7 family and cancer therapy: costimulation and coinhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Activation of thymic regeneration in mice and humans following androgen blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Immune responses to Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Development of a Listeria monocytogenes based vaccine against prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Improved endpoints for cancer immunotherapy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

CD4+ and CD8+ cells in cryopreserved human PBMC maintain full functionality in cytokine ELISPOT assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Immunologic monitoring of clinical trials in patients with cancer: technology versus common sense

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2012.07.004

10.1016/J.UCL.2012.07.004

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference